Order Article Reprints

Byun S, Lee SN, Lim S, Choo EH, Choi IJ, Kim CJ, Moon D, Park M-W, Park CS, Ahn Y, et al. Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors. Journal of Clinical Medicine. 2022; 11(22):6856. https://doi.org/10.3390/jcm11226856

Byun, Sungwook, Su Nam Lee, Sungmin Lim, Eun Ho Choo, Ik Jun Choi, Chan Joon Kim, Donggyu Moon, Mahn-Won Park, Chul Soo Park, Youngkeun Ahn, and et al. 2022. "Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors" Journal of Clinical Medicine 11, no. 22: 6856. https://doi.org/10.3390/jcm11226856

Byun, S., Lee, S. N., Lim, S., Choo, E. H., Choi, I. J., Kim, C. J., Moon, D., Park, M.-W., Park, C. S., Ahn, Y., Jeong, M.-H., & Chang, K. (2022). Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors. Journal of Clinical Medicine, 11(22), 6856. https://doi.org/10.3390/jcm11226856